MedPath

Quantitative Ultrasound(DeepUSFF) vs MRI-PDFF for Liver Fat Assessment in MASLD

Not Applicable
Recruiting
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Hepatic Steatosis
Liver Disease Parenchymal
Registration Number
NCT07192159
Lead Sponsor
Seoul National University Hospital
Brief Summary

This multicenter prospective study aims to evaluate the correlation between quantitative ultrasound fat fraction (USFF) and MRI-PDFF (Proton Density Fat Fraction) for liver fat quantification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The study will compare the diagnostic accuracy of quantitative ultrasound imaging against MRI-PDFF as the reference standard.

Detailed Description

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common liver disease requiring accurate assessment for treatment planning and monitoring. While liver biopsy remains the gold standard, it is invasive with potential complications. MRI-PDFF has emerged as an accurate non-invasive method, but it is expensive and has limited accessibility. Quantitative ultrasound techniques using RF data have been developed to provide objective liver fat assessment.

Objective: To prospectively evaluate the correlation between quantitative ultrasound-derived fat fraction (DeepUSFF) and MRI-PDFF in patients with suspected MASLD across different ethnicities and varying degrees of hepatic steatosis.

Methods: This prospective multicenter study will recruit 62 patients (31 from each participating center) suspected of having MASLD. All participants will undergo both quantitative ultrasound examination and non-contrast liver MRI within one week. The primary endpoint is the correlation coefficient between ultrasound fat fraction and MRI-PDFF. Secondary endpoints include diagnostic accuracy metrics and inter-observer reproducibility.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
62
Inclusion Criteria
  • Patients with clinically suspected MASLD based on abnormal ultrasound or liver function tests requiring liver ultrasound or MRI examination
  • BMI ≥25 kg/m² or waist circumference >90 cm (male) or >80 cm (female), suggesting high likelihood of fatty liver disease
  • Living liver transplant donors requiring preoperative liver ultrasound or MRI examination
  • Age ≥18 years
  • Understanding and signing informed consent
Exclusion Criteria
  • Significant alcohol consumption in the past 2 years:

Male: ≥30-60g/day average alcohol intake Female: ≥20-50g/day average alcohol intake

-Chronic liver disease:

Histological diagnosis of chronic liver disease HBsAg positive Anti-HCV positive Other suspected chronic liver diseases

-Liver failure:

Serum albumin <3.2 g/dL INR >1.3 Direct bilirubin >1.3 mg/dL

  • History of esophageal varices, ascites, hepatic encephalopathy, or acute biliary obstruction
  • History of liver cancer diagnosis or treatment
  • History of liver surgery
  • Pregnancy
  • Inability to obtain adequate liver ultrasound imaging:

Patient cooperation impossible Inadequate image acquisition as determined by investigator

-Inability to obtain adequate liver MRI imaging: Patient cooperation impossible Severe obesity preventing MRI examination MRI contraindications (cardiac pacemaker, etc.) Other factors preventing adequate imaging as determined by investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Correlation between Ultrasound Fat Fraction and MRI-PDFFAt enrollment (single time point assessment)

Measure: Pearson correlation coefficient between quantitative ultrasound fat fraction (USFF) and MRI-PDFF

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

southwoods imaging (Northeastern Ohio Radiology Research and Education Fund )

🇺🇸

Boardman, Ohio, United States

Seoul National University Hospital

🇰🇷

Seoul, Seoul, South Korea

southwoods imaging (Northeastern Ohio Radiology Research and Education Fund )
🇺🇸Boardman, Ohio, United States
Richard Barr, MD
Contact
+13307706925
rgbarr525@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.